Mounjaro 2.5mg reviews: what the trial data actually shows at the starting dose

Why the trial data looks quiet at 2.5mg, and what that means for reviews

The SURMOUNT-1 study did not report outcomes at each individual dose step; it measured total weight reduction across 72 weeks of treatment, titrating participants toward 5mg, 10mg and 15mg. This is worth knowing when you read reviews, because most people at 2.5mg are four weeks in. Their bodies are adjusting to a dual GIP and GLP-1 receptor agonist for the first time. Appetite suppression exists at this dose but is usually modest. Visible changes on the scales are often small. That is normal, expected, and built into the prescribing schedule from the start.

A common misconception is that a quiet first month means the medicine is not working. In practice, the 2.5mg period is doing quiet but real work: your digestive system is learning to tolerate tirzepatide so that higher doses can be reached safely. The NHS medicines page for tirzepatide describes the starter dose explicitly as a way to reduce side effects before dose escalation, not as a therapeutic ceiling. People who understand this going in tend to write calmer, more useful reviews of the 2.5mg phase than those who expected dramatic results in week one.

If you want a comparison point for how the experience evolves, accounts from people further into treatment are collected on the Mounjaro 5mg reviews page.

What people actually report during the first four weeks

Reviews of the 2.5mg phase cluster around a few consistent themes. Appetite changes are the first thing most people notice: not a dramatic loss of interest in food, but a subtle reduction in portion size or a slower return of hunger after meals. Some people feel very little different at all for the first week or two, which can be unsettling if expectations were set by accounts of later doses.

The side effects that dominate early reviews are gastrointestinal: nausea (often mild, frequently described as a background queasiness rather than acute illness), occasional constipation or looser stools, and indigestion or reflux. Fatigue in the first few days is also mentioned. These effects are most pronounced immediately after the injection and typically ease within days, though for some people they persist into the second or third week. The pattern is consistent with what the SURMOUNT-1 trial recorded, GI effects were the most common adverse events across all dose groups, with the sharpest incidence early and at each dose step upward.

Reviews that describe the 2.5mg phase as uneventful are not unusual and are not a sign that something is wrong. Prescribers hear this regularly: the absence of dramatic effects at the start is not a warning sign. The full picture of how your treatment is going emerges across months, not in the first pen.

How the prescribing schedule shapes what you can fairly expect

Mounjaro is available in six UK strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg. The prescriber determines the pace of escalation, typically moving upward in four-week steps when the current dose is well tolerated. This is not arbitrary. Each step allows the body to adjust before a higher concentration reaches the receptors involved in appetite and gastric emptying. Rushing escalation does not improve results and tends to worsen side effects.

For a sense of what the cost of private treatment looks like across a course of escalation, the Mounjaro cost page covers what the private market looks like and what a legitimate price should include. It is worth reading before starting, so the full picture of a multi-month treatment is clear from the outset.

People who reach 10mg or 15mg often describe the 2.5mg phase retrospectively as the least eventful part of treatment. Reviews from those further along (including accounts specifically focused on weight loss at 2.5mg) reflect how much the experience shifts once therapeutic doses are sustained, and you can read about that progression in detail on the 7.5mg Mounjaro reviews page or, for those who have moved further still, on the Mounjaro 10mg reviews page where people share how their results developed at that stage. The full Mounjaro overview covers the complete arc of treatment for anyone wanting the broader picture before committing.

Safety considerations specific to the early weeks

The 2.5mg phase is when the body is most likely to flag an incompatibility, which is one reason clinical review before and during treatment matters. The side effects most worth monitoring in the first weeks are those that cross from discomfort into something that needs attention: severe or persistent abdominal pain that extends toward the back should prompt urgent medical advice, as this can be a sign of pancreatitis, flagged in a January 2026 MHRA Drug Safety Update as an infrequent but potentially serious effect of GLP-1 medicines. Signs of an allergic reaction, significant dehydration from GI illness, or any mood changes that concern you also warrant contact with your healthcare team rather than a wait-and-see approach.

Contraception is worth raising before you start. Women taking an oral contraceptive pill are advised to use an additional non-oral method for the first four weeks of Mounjaro treatment and for four weeks after each dose increase, as absorption of the pill may be reduced. This is specific to tirzepatide; the mechanism does not apply in the same way to semaglutide. If you have any questions about this or about how to report side effects through the Yellow Card scheme, our clinical team can help. A prescriber at our pharmacy reviews every consultation personally before treatment is approved, and is available after it starts.

When you are ready to talk through whether treatment is suitable for you, start your free consultation and a prescriber will review your answers the same day.